Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and MMF in Highly Sensitized Renal Transplant Candidates
NCT00446251Phase 2Completed
- Sponsor
- University of Washington
- Start
- Dec 2006
- Primary completion
- Apr 2008
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of rituximab in Human Leukocyte Antigen Sensitization, sponsored by University of Washington. Primary endpoint: Number of Subjects Who Experience a Decrease in Their Panel of Reactive Antibodies (PRA) at 6 Months. Started Dec 2006; status: completed.
02
Drugs
rituximab
03
Conditions
Human Leukocyte Antigen Sensitization
Beyond the preview
Go deeper on NCT00446251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00446251.